Comanche lines up trial for preeclampsia siRNA with Moderna, Medicines Company vets and GV backing

Kyle LaHucik

Senior Reporter

A new siRNA biotech from Moderna and Medicines Company veterans is nearing the clinic as it looks to address rising maternal health risks and reduce …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Comanche lines up trial for preeclampsia siRNA with Moderna, Medicines Company vets and GV backing

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Makary, in one of first comments on FDA policy, floats new pathway for rare disease drugs

China startup injects CRISPR therapy into the brain for the first time

Trodelvy and Keytruda combo succeeds in Phase 3 breast cancer study

Roivant brings rare disease program closer as Immunovant CEO retires

FDA plans to ban pharma employees from serving on adcomms. The impact will be limited

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Co­manche lines up tri­al for preeclamp­sia siR­NA with Mod­er­na, Med­i­cines Com­pa­ny vets and GV back­ing

Senior Reporter

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Comanche lines up trial for preeclampsia siRNA with Moderna, Medicines Company vets and GV backing